Faculty profile
George Sandor
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Lancet (London, England) · 2022
Characterization of Myocardial Repolarization Reserve in Adolescent Females With Anorexia Nervosa.
Circulation · 2016
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.
American heart journal · 2015
Latest funding
- $669,376
The role of endothelial function in the pathogenesis and management of Marfan syndrome-associated aortic disease
CIHR · 2018 · Principal investigator
- $759,525
Cellular Mechanisms underlying vascular dysfunction & aortic aneurysm in Marfan syndrome
CIHR · 2010 · Co-investigator
3 publications.
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, Wilson K, Reith C, Child AH, Clayton T, Dodd M, Flather M, Jin XY, Sandor G, Groenink M, Mulder B, De Backer J, Evangelista A, Forteza A, Teixido-Turà G, Boileau C, Jondeau G, Milleron O, Lacro RV, Sleeper LA, Chiu HH, Wu MH, Neubauer S, Watkins H, Dietz H, Baigent C, Marfan Treatment Trialists’ Collaboration
Characterization of Myocardial Repolarization Reserve in Adolescent Females With Anorexia Nervosa.
Padfield GJ, Escudero CA, DeSouza AM, Steinberg C, Gibbs K, Puyat JH, Lam PY, Sanatani S, Sherwin E, Potts JE, Sandor G, Krahn AD
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.
Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM, Arbustini E, Erdem G, Jin XY, Flather MD, Mullen MJ, Child AH, Forteza A, Evangelista A, Chiu HH, Wu MH, Sandor G, Bhatt AB, Creager MA, Devereux RB, Loeys B, Forfar JC, Neubauer S, Watkins H, Boileau C, Jondeau G, Dietz HC, Baigent C
The role of endothelial function in the pathogenesis and management of Marfan syndrome-associated aortic disease
Principal investigators: Bernatchez, Pascal N; Esfandiarei, Mitra; Harris, Kevin; Potts, James E; Sandor, George G; Van Breemen, Cornelis C
Keywords: Aorta; Endothelial Function; Endothelium; Losartan; Marfan
Cellular Mechanisms underlying vascular dysfunction & aortic aneurysm in Marfan syndrome
Principal investigators: Van Breemen, Cornelis C
Keywords: Aortic Aneurysm; Cell & Molecular Biology; Disease Biomarker; Histopathology/Pathophysiology; Human Aortic Explants; In Vivo Pharmacology; Signalling Pathway; Whole Organ &Cell Culture
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.